The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.
Preet Paul Singh
No relevant relationships to disclose
Wilson I. Gonsalves
No relevant relationships to disclose
Vinay Gupta
No relevant relationships to disclose
Francis Buadi
No relevant relationships to disclose
Martha Lacy
Research Funding - Celgene
Angela Dispenzieri
Research Funding - Celgene; Janssen; Millennium; Pfizer
Morie Gertz
No relevant relationships to disclose
Suzanne R. Hayman
No relevant relationships to disclose
David Dingli
No relevant relationships to disclose
Stephen J. Russell
No relevant relationships to disclose
John Anthony Lust
No relevant relationships to disclose
Steven R. Zeldenrust
No relevant relationships to disclose
Prashant Kapoor
No relevant relationships to disclose
Arleigh Robertson McCurdy
No relevant relationships to disclose
S. Vincent Rajkumar
No relevant relationships to disclose
Shaji Kumar
No relevant relationships to disclose